Advanced Filters
noise

Human Papilloma Virus Clinical Trials

A listing of Human Papilloma Virus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 203 clinical trials

HPV Vaccine Reduced Dose

This study aims to answer the question: does 1-dose HPV vaccination generate the same immune responses compared to 2- or 3-dose HPV vaccination? This will be done by studying the immune response in blood, lymph nodes, and bone marrow. Human papillomaviruses (HPV) cause cancers (cervical, anal, oropharyngeal, vulvar, vaginal, and …

18 - 45 years of age All Phase 4
M Minge Xu

Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC

This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). MRD is defined as ctDNA detection in …

18 years of age All Phase 2
Y Yue He, M.D.

Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL

This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD08 administered by intramuscular (IM) injection followed by electroporation (EP) in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 \[CIN2\] or grade 3 \[CIN3\]) …

18 - 60 years of age Female Phase 2
F Fang Jiang, M.D.

NWRD09 for HPV-16 Related Cervical HSIL

This is a single-arm, open label, multi-center clinical study to evaluate the safety, tolerability and immunogenicity HPV16 targeted mRNA therapeutic vaccine (NWRD09) in HPV16 related cervical high-grade squamous intraepithelial lesions (HSlL).

18 - 65 years of age Female Phase 1
K Keneshia K Lane, B.A.

HPV Vaccine, Imiquimod, and Metformin Combination Trial

The goal of this clinical trial is to explore whether additional treatments can help strengthen the participant's immune system to fight cancer caused by the Human Papillomavirus (HPV), a virus spread through intimate skin-to-skin contact. The trial will also monitor the safety of these treatments. The main questions it aims …

18 - 64 years of age Female Phase 2
S Sara Pai, MD, PHD

CUE-101with Pembrolizumab for LA-HPV+HNSCCs

This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101 monotherapy, and CUE-101 in combination with pembrolizumab as neoadjuvant therapy in HLA-A\*0201-positive treatment naive participants with locally advanced, unresectable HPV-16 associated head and neck squamous cell carcinoma (HNSCC).

18 years of age All Phase 2
M Menekse Göker, med.

Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination

The current study is an open-label, non-randomized, longitudinal exploratory trial using the licensed Gardasil 9 (9vHPV) vaccine in an off-label context to investigate biological and immunological outcomes in human papillomavirus type 16 (HPV16) positive women. Two doses of the licensed Gardasil 9 vaccine will be administered to approximately 50 women …

18 - 45 years of age Female Phase 2
S Site Public Contact

Detecting HPV DNA in Anal and Cervical Cancers

This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer. Doctors leading this study will use blood tests to find out if they can detect the HPV virus in the blood …

18 years of age All Phase N/A
E Elizabeth Y. Chiao

Screening Women With Prior HPV for Anal Neoplasia

The goal of this single arm trial is to prospectively evaluate screening methods for anal cancer precursors in HIV uninfected women with a history of lower genital tract neoplasias and cancers.

35 years of age Female Phase N/A
F Fang Li, M.D.,PH.D.

HUC-MSC for Treatment of High-risk HPV Infection

To evaluate the safety and initial effectiveness of human umbilical cord mesenchymal stem cells in HPV clearance.

25 - 60 years of age Female Phase 1/2

Simplify language using AI